Luminex Co. (LMNX) Shares Bought by Algert Global LLC

Algert Global LLC increased its position in Luminex Co. (NASDAQ:LMNX) by 18.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 129,997 shares of the medical instruments supplier’s stock after acquiring an additional 20,043 shares during the quarter. Algert Global LLC owned about 0.30% of Luminex worth $2,643,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Teachers Advisors LLC lifted its holdings in Luminex by 4.7% during the 1st quarter. Teachers Advisors LLC now owns 87,489 shares of the medical instruments supplier’s stock valued at $1,607,000 after purchasing an additional 3,950 shares during the last quarter. Aperio Group LLC lifted its holdings in Luminex by 190.9% during the 2nd quarter. Aperio Group LLC now owns 35,594 shares of the medical instruments supplier’s stock valued at $752,000 after purchasing an additional 23,357 shares during the last quarter. Strs Ohio lifted its holdings in Luminex by 6.2% during the 2nd quarter. Strs Ohio now owns 24,100 shares of the medical instruments supplier’s stock valued at $508,000 after purchasing an additional 1,400 shares during the last quarter. Great West Life Assurance Co. Can lifted its holdings in Luminex by 9.3% during the 2nd quarter. Great West Life Assurance Co. Can now owns 58,999 shares of the medical instruments supplier’s stock valued at $1,245,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Texas Permanent School Fund lifted its holdings in Luminex by 8.2% during the 2nd quarter. Texas Permanent School Fund now owns 29,184 shares of the medical instruments supplier’s stock valued at $616,000 after purchasing an additional 2,207 shares during the last quarter. Institutional investors own 79.16% of the company’s stock.

Shares of Luminex Co. (NASDAQ:LMNX) traded down $0.08 on Friday, hitting $19.70. 161,118 shares of the stock traded hands, compared to its average volume of 200,208. The company has a market capitalization of $871.40, a price-to-earnings ratio of 34.10, a PEG ratio of 2.48 and a beta of 0.19. Luminex Co. has a 52 week low of $17.68 and a 52 week high of $22.42.

Luminex (NASDAQ:LMNX) last released its quarterly earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.06. Luminex had a net margin of 9.52% and a return on equity of 6.01%. The business had revenue of $74.14 million for the quarter, compared to the consensus estimate of $74.38 million. During the same period in the prior year, the company posted $0.21 earnings per share. Luminex’s revenue was up 4.1% compared to the same quarter last year. analysts anticipate that Luminex Co. will post 0.49 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 12th. Shareholders of record on Friday, December 22nd will be paid a dividend of $0.06 per share. The ex-dividend date of this dividend is Thursday, December 21st. This represents a $0.24 dividend on an annualized basis and a yield of 1.22%. Luminex’s payout ratio is 36.36%.

In related news, Director G Walter Loewenbaum II sold 39,456 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $20.40, for a total value of $804,902.40. Following the completion of the transaction, the director now owns 651,736 shares in the company, valued at approximately $13,295,414.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last quarter, insiders sold 131,698 shares of company stock valued at $2,761,201. 6.90% of the stock is owned by company insiders.

A number of research firms recently weighed in on LMNX. TheStreet upgraded shares of Luminex from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Jefferies Group reiterated a “hold” rating and issued a $21.00 price target on shares of Luminex in a report on Friday, October 20th. ValuEngine upgraded shares of Luminex from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Finally, BidaskClub cut shares of Luminex from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $20.00.

ILLEGAL ACTIVITY WARNING: “Luminex Co. (LMNX) Shares Bought by Algert Global LLC” was posted by Week Herald and is the property of of Week Herald. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://weekherald.com/2017/12/30/luminex-co-lmnx-stake-lifted-by-algert-global-llc.html.

Luminex Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply